These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26139550)

  • 41. Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Shoukier M; Kubiak M; Cortes J
    Curr Oncol Rep; 2021 Jun; 23(8):91. PubMed ID: 34125316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
    Molica M; Scalzulli E; Colafigli G; Fegatelli DA; Massaro F; Latagliata R; Foà R; Breccia M
    Ann Hematol; 2018 Oct; 97(10):1803-1808. PubMed ID: 29806063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
    Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
    Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
    Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
    IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
    Yilmaz M; Jabbour E
    Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 48. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
    Tokuhira M; Kimura Y; Sugimoto K; Nakazato T; Ishikawa M; Fujioka I; Takaku T; Iriyama N; Sato E; Fujita H; Hatta Y; Komatsu N; Asou N; Kizaki M; Kawaguchi T
    Med Oncol; 2018 Feb; 35(3):38. PubMed ID: 29442179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
    Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
    Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The link between interleukin-1β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.
    Mori H; Sukegawa M; Fukatsu M; Sano T; Takahashi H; Harada K; Kimura S; Ohkawara H; Nakamura K; Mita M; Saito T; Hamazaki Y; Ohta M; Ikezoe T
    Ann Hematol; 2020 Feb; 99(2):359-361. PubMed ID: 31872359
    [No Abstract]   [Full Text] [Related]  

  • 52. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.
    Bocchia M; Galimberti S; Aprile L; Sicuranza A; Gozzini A; Santilli F; Abruzzese E; Baratè C; Scappini B; Fontanelli G; Trawinska MM; Defina M; Gozzetti A; Bosi A; Petrini M; Puccetti L
    Oncotarget; 2016 Nov; 7(44):72311-72321. PubMed ID: 27527867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
    Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
    Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
    Valent P; Gastl G; Geissler K; Greil R; Hantschel O; Lang A; Linkesch W; Lion T; Petzer AL; Pittermann E; Pleyer L; Thaler J; Wolf D
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):370-7. PubMed ID: 21903413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
    Barber MC; Mauro MJ; Moslehi J
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):110-114. PubMed ID: 29222244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
    Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
    Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
    Valent P; Hadzijusufovic E; Schernthaner GH; Wolf D; Rea D; le Coutre P
    Blood; 2015 Feb; 125(6):901-6. PubMed ID: 25525119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
    Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
    J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.